Abstract
Paclitaxel (Taxol) resistance remains a major obstacle for the successful treatment of ovarian cancer. MicroRNAs (miRNAs) have oncogenic and tumor suppressor activity and are associated with poor prognosis phenotypes. miRNA screenings for this drug resistance are needed to estimate the prognosis of the disease and find better drug targets. miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan–Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. A total of 82 miRNAs were identified in ovarian carcinoma cells compared to normal ovarian cells. miR-141, miR-106a, miR-200c, miR-96, and miR-378 were overexpressed, and miR-411, miR-432, miR-494, miR-409-3p, and miR-655 were underexpressed in ovarian cancer cells. Seventeen miRNAs were overexpressed in Taxol-resistant cells, including miR-663, miR-622, and HS_188. Underexpressed miRNAs in Taxol-sensitive cells included miR-497, miR-187, miR-195, and miR-107. We further showed miR-663 and miR-622 as significant prognosis markers of the chemo-resistant patient group. In particular, the downregulation of the two miRNAs was associated with better survival, perhaps increasing the sensitivity of cancer cells to Taxol. In the chemo-sensitive patient group, only miR-647 could be a prognosis marker. These miRNAs inhibit several interacting genes of p53 networks, especially in TUOS-3 and TUOS-4, and showed cell line-specific inhibition effects. Taken together, the data indicate that the three miRNAs are closely associated with Taxol resistance and potentially better prognosis factors. Our results suggest that these miRNAs were successfully and reliably identified and would be used in the development of miRNA therapies in treating ovarian cancer.
Supplementary material
Abbreviation: miRNA, micro rubonucleic acid.
Abbreviations: CT, threshold cycle; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; miRNA, micro rubonucleic acid.
Abbreviations: CT, threshold cycle; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; miRNA, micro rubonucleic acid.
Abbreviation: MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
Abbreviations: CT, threshold cycle; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; miRNA, micro rubonucleic acid.
Abbreviations: CT, threshold cycle; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; miRNA, micro rubonucleic acid.
Abbreviation: miRNA, micro rubonucleic acid.
Abbreviations: CT, threshold cycle; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; miRNA, micro rubonucleic acid.
Abbreviation: miRNA, micro rubonucleic acid.
Abbreviation: miRNA, micro rubonucleic acid.
Acknowledgments
We deeply thank PhD student Pankaj Kumar Chaturvedi for his active advice and support. We are also indebted to PhD student Gantumur Battogtokh for his efforts.
Disclosure
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (NRF-2012R1A2A1A03670430) and a grant (Industry-Ac ademic Cooperation Foundation program) from the Diatech Korea Co. Ltd, Seoul, Republic of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors report no other conflicts of interest in this work.